Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice

INTRODUCTION: The treatment of choice for Atypical Hemolytic Uremic Syndrome (aHUS) is the monoclonal antibody eculizumab. The objective of this study was to assess the efficacy and safety of eculizumab in a cohort of kidney transplant patients suffering from aHUS. METHODS: Description of the prospe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: de Andrade, Luis Gustavo Modelli, Contti, Mariana Moraes, Nga, Hong Si, Bravin, Ariane Moyses, Takase, Henrique Mochida, Viero, Rosa Marlene, da Silva, Trycia Nunes, Chagas, Kelem De Nardi, Palma, Lilian Monteiro Pereira
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685617/
https://ncbi.nlm.nih.gov/pubmed/29136640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0188155
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados